Table 2: Synopsis of biomarkers in the GERD-BE-EAC axis. According to Table 1, most promising biomarkers are summarized indicating that only dysplasia is involved in all four categories. Dysplasia can be used as diagnostic biomarker as well as to assess the risk of progression to EAC or response to therapy and is associated with poor survival ( survival).

DysplasiaP53P16P21Growth factorsCell cycle

A = Diagnostic Biomarker
B = Progression Biomarker
C = Predictive Biomarker
D = Prognostic Biomarker survival survival survival